



FOR IMMEDIATE RELEASE

BIOLEX AND MEDAREX
SIGN RESEARCH COLLABORATION AGREEMENT

Eleventh Partner Protein to Begin Commercial Line Creation Using LEX System™

PITTSBORO, NC, FEBRUARY 4, 2005: Biolex, Inc., a privately held protein therapeutics company, today announced the signing of a new agreement with Medarex, Inc. (Nasdaq: MEDX), an antibody therapeutics company, to create a commercial line for an undisclosed Medarex monoclonal antibody using the Biolex LEX System™. Including this project, Biolex has a total of eleven partner proteins with five different top-tier partners to date, two of which have already advanced to GLP scale-up production.

“I am excited to be adding another antibody to our Partner Proteins portfolio of products in evaluation using our unique approach to protein production,” said Jan Turek, President and CEO of Biolex. “We are pleased that a company such as Medarex, with longstanding monoclonal antibody expertise, sees the potential advantages of using the LEX System™ and recognizes the value of new approaches to protein expression.”

Biolex will implement a Commercial Line Creation project using its proprietary LEX System™ for one of Medarex’ clinical-stage monoclonal antibodies. At Medarex’ option, Biolex may scale-up and manufacture the antibody following the commercial line creation phase. Financial terms of the collaboration have not been disclosed.

About Biolex: Biolex, Inc. is a private, venture capital-backed biopharmaceutical company. Biolex is developing recombinant human therapeutic proteins that, until now, have been impossible or very expensive to develop in existing expression systems. Biolex’ proprietary LEX System™ has demonstrated speed, regulatory and economic benefits with hard-to-make proteins and monoclonal antibodies. Biolex has a pipeline of proprietary products in development, and is partnering with pharmaceutical and biotechnology companies seeking the protein development and production benefits the LEX System™ offers. Biolex has entered into corporate partnerships with Bayer HealthCare LLC, Centocor, Inc., Debiopharm S.A., and a major pharmaceutical company. The Company’s headquarters, research laboratories and clinical manufacturing facilities are based in Pittsboro, North Carolina. Visit the Company’s web site at www.biolex.com.

Contact: John Irick, Senior Vice President and Chief Business Officer, Biolex, Inc., 919-542-9901; Michelle Linn, Linnden Communications, 508-869-0138, michlinn@charter.net.

###

